All In Biotech

Investigational drug · Phase 2

Adjuvanted RSVPreF3 vaccine

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cardiovascular Disease, Respiratory Syncytial Virus Infections.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

6

Any phase or sponsor naming "Adjuvanted RSVPreF3 vaccine"

First trial start

2025

Aug 6, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Adjuvanted RSVPreF3 vaccine", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Cardiovascular Disease
  • Respiratory Syncytial Virus Infections

Approved drugs for the same conditions: RSV · Cardiovascular and metabolic · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "Adjuvanted RSVPreF3 vaccine" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 25 on PubMed

Also in development for Cardiovascular Disease

  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • AZD0780Phase 36 trials

    AstraZeneca · Cardiovascular Disease, Dyslipidaemia, Heterozygous Familial Hypercholesterolaemia

  • OlpasiranAMG 890Phase 33 trials

    Amgen · Cardiovascular Disease, Atherosclerotic Cardiovascular Disease

  • ClazakizumabLY5724886, CSL300Phase 32 trials

    Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity

  • VERVE-102LY4636581Phase 21 trial

    Eli Lilly · Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.